AdaptHealth/$AHCO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About AdaptHealth
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
- Ticker
- $AHCO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 10,900
- Headquarters
- Conshohocken, United States
- Website
- adapthealth.com
AdaptHealth Metrics
BasicAdvanced
$1B
-
-$2.99
1.32
-
Price and volume
Market cap
$1B
Beta
1.32
52-week high
$13.43
52-week low
$5.21
Average daily volume
2.6M
Financial strength
Current ratio
1.127
Quick ratio
0.64
Long term debt to equity
1.605
Total debt to equity
1.662
Interest coverage (TTM)
1.26%
Profitability
EBITDA (TTM)
588.067
Gross margin (TTM)
18.19%
Net profit margin (TTM)
-11.83%
Operating margin (TTM)
3.84%
Effective tax rate (TTM)
7.28%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
1.92%
Return on equity (TTM)
-28.37%
Valuation
Price to revenue (TTM)
0.309
Price to book
0.84
Price to tangible book (TTM)
-1.09
Price to free cash flow (TTM)
12.943
Free cash flow yield (TTM)
7.73%
Free cash flow per share (TTM)
0.603
Growth
Revenue change (TTM)
21.41%
Earnings per share change (TTM)
-633.58%
3-year revenue growth (CAGR)
3.25%
3-year earnings per share growth (CAGR)
-4.44%
What the Analysts think about AdaptHealth
Analyst ratings (Buy, Hold, Sell) for AdaptHealth stock.
Analyst projections of the future price of AdaptHealth stock.
Bulls say / Bears say
Third-quarter revenue rose 10.9% year on year, with 12.8% organic growth across all continuing segments. AdaptHealth raised its full-year revenue and adjusted EBITDA guidance after beating its targets. (SEC)
The largest capitated contract moved from a negative 4% margin in the second quarter to about 10% in the third, as lower costs and staffing changes improved performance. Management says the contract is now contributing positively to adjusted EBITDA. (The Motley Fool)
The planned $235 million Diabetes Health sale would leave AdaptHealth focused on sleep, respiratory and home medical equipment, and management expects to use sale proceeds to reduce debt. The deal has cleared the Hart-Scott-Rodino waiting period and is on track to close in early 2027, subject to other approvals. (AdaptHealth, SEC)
Cash generation has weakened sharply: year-to-date free cash flow was $2.6 million, against $140.1 million a year earlier. The company also cut its full-year free-cash-flow outlook, even as it raised revenue and adjusted EBITDA guidance. (SEC)
Adjusted EBITDA fell 2.9% year on year in the third quarter, and its margin narrowed to 19% from 21.7% despite revenue growth. The $168.2 million net loss also included a $184.8 million goodwill write-down. (SEC)
The biggest capitated contract is improving but remains exposed to high service use and costly urgent orders; its third-quarter margin was about 10%, with management targeting 20% only by late 2027. S&P warned that the contract lacks protection against these costs and kept a negative outlook on the company’s credit rating. (The Motley Fool, S&P Global Ratings)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
AdaptHealth Financial Performance
Revenues and expenses
AdaptHealth Earnings Performance
Company profitability
Upcoming events
No upcoming events
AdaptHealth News
AllArticlesVideos
Funds containing AdaptHealth
AllUSDEURGBP
Fund name | Fund size | $AHCO weighting |
|---|---|---|
iShares Ageing Population€AGED | $887M | 0.07% |
iShares Ageing Population£AGES | $887M | 0.07% |
iShares Ageing Population$AGED | $953M | 0.07% |
iShares S&P Small Cap 600£ISP6 | $2.5B | 0.04% |
iShares S&P SmallCap 600$IDP6 | $2.5B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.